gabapentin has been researched along with Convulsive Generalized Seizure Disorder in 15 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epilepsy is a chronic disease of the central nervous system characterized by recurrent epileptic seizures." | 3.01 | Second Generation of Antiepileptic Drugs and Oxidative Stress. ( Czuczwar, SJ; Kamieniak, M; Kośmider, K; Miziak, B, 2023) |
| "Gabapentin at a dosage of 1200 mg/d is safe and effective in treatment of epilepsy." | 2.71 | [Curative effect of gabapentin on refractory epilepsy]. ( Ding, MP; Hong, Z; Lü, CZ; Ma, GY; Pan, YF; Pan, YZ; Wang, DS; Wang, DX; Xiao, B; Zhao, QC; Zhu, GX, 2005) |
| "Gabapentin was well tolerated by patients in both dosage groups, and no patients exited the study due to adverse events, despite rapid initiation of full dose within 24 hours." | 2.68 | Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. ( Bergey, GK; Blume, WT; Crockatt, JG; Garofalo, E; LaMoreaux, L; Leiderman, DB; Morrell, MJ; Morris, HH; Penovich, PE; Pierce, M; Rosenfeld, W, 1997) |
| " Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups." | 2.68 | Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. ( Abou-Khalil, B; Beydoun, A; Cantrell, D; Fischer, J; Garofalo, E; Greiner, M; Harden, C; Hayes, A; Labar, DR; Pierce, M; Ramsay, RE; Sackellares, JC; Uthman, BM, 1997) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Gabapentin has few drug-drug interactions, none of which is clinically limiting." | 2.40 | Gabapentin in the management of convulsive disorders. ( McLean, MJ, 1999) |
| "Lamotrigine is a useful add-on therapy in treating children with epilepsy." | 1.33 | The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. ( Keegan, MB; Madden, D; McDonald, DG; McMenamin, JB; Najam, Y; Whooley, M, 2005) |
| " Both effects exhibited a tendency to a U-shaped dose-response curve." | 1.30 | Anticonvulsant action of gabapentin during postnatal development in rats. ( Haugvicová, R; Mares, P, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kośmider, K | 1 |
| Kamieniak, M | 1 |
| Czuczwar, SJ | 1 |
| Miziak, B | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Marson, AG | 2 |
| French, JA | 3 |
| Kanner, AM | 3 |
| Bautista, J | 3 |
| Abou-Khalil, B | 4 |
| Browne, T | 3 |
| Harden, CL | 3 |
| Theodore, WH | 3 |
| Bazil, C | 3 |
| Stern, J | 3 |
| Schachter, SC | 3 |
| Bergen, D | 3 |
| Hirtz, D | 3 |
| Montouris, GD | 3 |
| Nespeca, M | 3 |
| Gidal, B | 3 |
| Marks, WJ | 3 |
| Turk, WR | 3 |
| Fischer, JH | 3 |
| Bourgeois, B | 3 |
| Wilner, A | 3 |
| Faught, RE | 3 |
| Sachdeo, RC | 3 |
| Beydoun, A | 4 |
| Glauser, TA | 3 |
| McDonald, DG | 1 |
| Najam, Y | 1 |
| Keegan, MB | 1 |
| Whooley, M | 1 |
| Madden, D | 1 |
| McMenamin, JB | 1 |
| Zhu, GX | 1 |
| Ding, MP | 1 |
| Xiao, B | 1 |
| Wang, DX | 1 |
| Wang, DS | 1 |
| Pan, YZ | 1 |
| Zhao, QC | 1 |
| Pan, YF | 1 |
| Ma, GY | 1 |
| Hong, Z | 1 |
| Lü, CZ | 1 |
| Macdonald, RL | 1 |
| Kelly, KM | 1 |
| Chadwick, D | 2 |
| Leiderman, DB | 2 |
| Sauermann, W | 1 |
| Alexander, J | 1 |
| Garofalo, E | 3 |
| Bergey, GK | 1 |
| Morris, HH | 1 |
| Rosenfeld, W | 1 |
| Blume, WT | 1 |
| Penovich, PE | 1 |
| Morrell, MJ | 1 |
| Crockatt, JG | 1 |
| LaMoreaux, L | 1 |
| Pierce, M | 2 |
| Fischer, J | 1 |
| Labar, DR | 1 |
| Harden, C | 1 |
| Cantrell, D | 1 |
| Uthman, BM | 1 |
| Sackellares, JC | 1 |
| Ramsay, RE | 1 |
| Hayes, A | 1 |
| Greiner, M | 1 |
| Mares, P | 1 |
| Haugvicová, R | 1 |
| McLean, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives[NCT00266149] | Phase 3 | 10 participants | Interventional | 2003-06-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for gabapentin and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Second Generation of Antiepileptic Drugs and Oxidative Stress.
Topics: Anticonvulsants; Carbamazepine; Diazepam; Epilepsy; Epilepsy, Generalized; Fructose; Gabapentin; Hum | 2023 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Antipsychotic Agents; Carbamazepine; Child; Clinic | 2004 |
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Tr | 2004 |
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epile
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Cyclohexan | 2004 |
Antiepileptic drug mechanisms of action.
Topics: Acetates; Action Potentials; Amines; Anticonvulsants; Calcium Channels; Cyclohexanecarboxylic Acids; | 1993 |
Gabapentin in the management of convulsive disorders.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohexane | 1999 |
5 trials available for gabapentin and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
[Curative effect of gabapentin on refractory epilepsy].
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; | 2005 |
Gabapentin in generalized seizures.
Topics: Acetates; Adolescent; Adult; Amines; Analysis of Variance; Anticonvulsants; Cyclohexanecarboxylic Ac | 1996 |
Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Rel | 1997 |
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecar | 1997 |
Gabapentin.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1991 |
2 other studies available for gabapentin and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood.
Topics: Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2005 |
Anticonvulsant action of gabapentin during postnatal development in rats.
Topics: Acetates; Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Cyclohexanecarboxylic Acids; Do | 1997 |